Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Capital Expenditures (2019 - 2025)

AVITA Medical (RCEL) has disclosed Capital Expenditures for 5 consecutive years, with $855000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 90.24% year-over-year to $855000.0, compared with a TTM value of $1.0 million through Dec 2025, down 89.04%, and an annual FY2025 reading of $1.0 million, down 89.04% over the prior year.
  • Capital Expenditures was $855000.0 for Q4 2025 at AVITA Medical, up from -$595000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $8.8 million in Q4 2024 and bottomed at -$805000.0 in Q2 2024.
  • Average Capital Expenditures over 4 years is $724375.0, with a median of $159000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures surged 12744344.44% in 2024, then crashed 1015.38% in 2025.
  • Year by year, Capital Expenditures stood at -$349000.0 in 2022, then soared by 463.04% to $1.3 million in 2023, then skyrocketed by 591.71% to $8.8 million in 2024, then tumbled by 90.24% to $855000.0 in 2025.
  • Business Quant data shows Capital Expenditures for RCEL at $855000.0 in Q4 2025, -$595000.0 in Q3 2025, and $524000.0 in Q2 2025.